{"gene":"SETDB2","run_date":"2026-06-10T07:46:31","timeline":{"discoveries":[{"year":2001,"finding":"SETDB2 (CLLD8) contains a methyl-CpG binding domain, a preSET domain, and a SET domain, suggesting it functions in methylation-mediated transcriptional repression; identified as a novel gene at chromosome 13q14.","method":"Sequence analysis and domain characterization","journal":"Cancer research","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational domain prediction only, no functional experiments performed in this paper","pmids":["11306461"],"is_preprint":false},{"year":2010,"finding":"SETDB2/CLLD8/KMT1F catalyzes trimethylation of histone H3K9 at interspersed repetitive elements and centromere-associated repeats, recruits heterochromatin protein 1 (HP1) to centromeres, and its depletion causes loss of CENP proteins and delayed mitosis, establishing a role in chromosome condensation and segregation. It acts in concert with SUV39H1/KMT1A.","method":"siRNA knockdown, ChIP, immunofluorescence, cell cycle analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (ChIP for H3K9me3, HP1 recruitment assay, CENP localization, mitosis timing) in a single focused study","pmids":["20404330"],"is_preprint":false},{"year":2010,"finding":"In zebrafish, Setdb2 (H3K9 methyltransferase) restricts dorsal organizer territory and regulates left-right asymmetry by suppressing fgf8 expression; knockdown expands organizer markers and increases fgf8 mRNA, and these defects are rescued by dominant-negative FGF receptor or fgf8 knockdown, placing Setdb2 upstream of Fgf8 signaling.","method":"Morpholino knockdown in zebrafish embryos, mRNA rescue, dominant-negative receptor epistasis, in situ hybridization","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with rescue experiments and multiple markers across two independent suppression strategies","pmids":["20133783"],"is_preprint":false},{"year":2014,"finding":"In influenza-infected mice, Setdb2 expression is induced by type I interferon signaling; Setdb2 occupies the Cxcl1 promoter and is required for H3K9me3 deposition there, repressing CXCL1 and other NF-κB target genes; hypomorphic Setdb2 mice show increased neutrophil infiltration and reduced susceptibility to bacterial superinfection, placing Setdb2 as a crosstalk mediator between type I IFN and NF-κB pathways.","method":"Gene-trap hypomorphic mouse model, ChIP (H3K9me3 at Cxcl1 promoter), gene expression analysis, neutrophil infiltration quantification","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model with ChIP demonstrating direct promoter occupancy and H3K9me3 deposition, replicated across multiple NF-κB target genes","pmids":["25419628"],"is_preprint":false},{"year":2014,"finding":"In zebrafish, Setdb2 regulates convergence and extension (C&E) movements during gastrulation by transcriptionally suppressing dvr1 (a TGF-β ligand) to an appropriate level; both knockdown and overexpression of dvr1 phenocopy C&E defects, placing Setdb2-dvr1 as a critical transcriptional cascade for body axis formation.","method":"Morpholino knockdown, epistasis rescue experiments, in situ hybridization in zebrafish embryos","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with rescue in a vertebrate developmental model, single lab","pmids":["24892953"],"is_preprint":false},{"year":2016,"finding":"SETDB2 is induced by glucocorticoid receptor (GR) signaling in liver; it facilitates GR chromatin enrichment and glucocorticoid-dependent enhancer-promoter interactions at the Insig2a locus, thereby inducing Insig2a expression during fasting; Insig2a in turn represses SREBP and limits lipid synthesis. SETDB2 knockdown prevents glucocorticoid-mediated inhibition of SREBP processing.","method":"ChIP, chromatin conformation (enhancer-promoter looping), siRNA knockdown in hepatocytes and in vivo, glucocorticoid treatment of ob/ob mice","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct chromatin enrichment plus functional knockdown with SREBP processing readout; multiple orthogonal methods in single lab","pmids":["27568546"],"is_preprint":false},{"year":2016,"finding":"SETDB2 catalyzes H3K9me3 at the promoter regions of tumor suppressor genes WWOX and CADM1 in gastric cancer cells, repressing their transcription; ectopic SETDB2 protein is recruited to these promoters as shown by ChIP, and SETDB2 knockdown reduces global H3K9me3 and de-represses these genes.","method":"ChIP (H3K9me3), siRNA knockdown, microarray gene expression, SETDB2 overexpression","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional knockdown/overexpression with gene expression readout, single lab","pmids":["27572307"],"is_preprint":false},{"year":2018,"finding":"SETDB2 is a direct transcriptional target of the E2A-PBX1 chimeric transcription factor in pre-BCR+ ALL; SETDB2 in turn deposits H3K9me3 at the CDKN2C promoter to repress this cell-cycle inhibitor, creating an oncogenic pathway downstream of E2A-PBX1 that silences a tumor suppressor.","method":"ChIP (H3K9me3 at CDKN2C promoter), shRNA knockdown in vitro and in vivo (xenograft), promoter analysis for E2A-PBX1 binding","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct promoter ChIP, in vitro and in vivo knockdown, epistasis established with multiple orthogonal methods","pmids":["29694893"],"is_preprint":false},{"year":2018,"finding":"In monocytes during systemic bacterial infection, elevated Setdb2 represses antifungal immunity genes (including Il1b, Tnf, Il6, Ifnb, Cxcl1) via H3K9 methylation at their promoters, promoting susceptibility to secondary Candida albicans super-infection; lentiviral Setdb2 knockout reverses this repression.","method":"Lentivirus-mediated Setdb2 knockout and overexpression in monocytes, gene expression analysis, murine super-infection model","journal":"Cellular microbiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic manipulation with functional readout, mechanism attributed to H3K9 methylation at promoters, single lab","pmids":["29749709"],"is_preprint":false},{"year":2019,"finding":"In wound macrophages, SETDB2 trimethylates histone H3 (H3K9me3) at NF-κB binding sites on inflammatory cytokine gene promoters to suppress their transcription; SETDB2 expression is regulated by IFNβ, and myeloid-specific deletion of Setdb2 impairs transition from inflammatory to reparative macrophage phenotype; under diabetic conditions the IFNβ-Setdb2 axis is impaired. Additionally, SETDB2 regulates xanthine oxidase expression and thus uric acid production.","method":"Myeloid-specific Setdb2 knockout mice, ChIP (H3K9me3 at NF-κB sites), IFNβ treatment, wound macrophage isolation from diabetic patients and controls","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo myeloid-specific KO plus ChIP on human and murine samples, multiple orthogonal methods, published in high-impact journal","pmids":["31350176"],"is_preprint":false},{"year":2019,"finding":"In influenza-associated encephalopathy, Setdb2 is upregulated in brain tissue and deposits H3K9me3 at the Caveolin-1 promoter to repress Caveolin-1 expression, contributing to blood-brain barrier breakdown; ChIP confirmed H3K9 methylation at the Caveolin-1 promoter.","method":"Murine IAE model (LPS + influenza), ChIP (H3K9me3 at Caveolin-1 promoter), gene expression profiling of 84 histone modification enzymes","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct promoter methylation plus in vivo model, single lab","pmids":["30670717"],"is_preprint":false},{"year":2020,"finding":"SETDB2 interacts with and methylates ΔNp63α protein, stabilizing it; SETDB2 also upregulates transcription of ΔNp63α downstream Hedgehog pathway genes; SETDB2 knockdown reduces breast cancer stem cell population and mammosphere formation, and restoring ΔNp63α rescues the defect.","method":"Co-immunoprecipitation (SETDB2–ΔNp63α interaction), in vitro methylation assay, shRNA knockdown, mammosphere formation assay, in vivo tumor initiation","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and methylation assay for protein-protein interaction and PTM, functional rescue experiment, single lab","pmids":["32549764"],"is_preprint":false},{"year":2021,"finding":"Coronavirus infection decreases SETDB2 in macrophages via reduction of IFNβ-JAK1/STAT3 signaling; decreased SETDB2 reduces H3K9me3 at NF-κB binding sites on inflammatory gene promoters, increasing macrophage-mediated inflammation; IFNβ treatment restores SETDB2 and represses inflammation; myeloid-specific Setdb2 KO mice show enhanced pathologic inflammation after coronavirus infection.","method":"Myeloid-specific Setdb2 KO mice, JAK/STAT pathway blockade, ChIP (H3K9me3 at NF-κB sites), IFNβ treatment, human SARS-CoV-2 patient monocytes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO model, ChIP, human patient samples, and pharmacologic pathway manipulation as orthogonal methods","pmids":["34479991"],"is_preprint":false},{"year":2021,"finding":"SETDB2 deficiency in hematopoietic cells promotes vascular inflammation and accelerates atherosclerosis; loss of SETDB2 in macrophages leads to increased monocyte populations, enhanced inflammatory gene expression, macrophage accumulation in plaques, and attenuated efferocytosis; SETDB2 expression is upregulated in M1 but not M2 macrophages.","method":"Bone marrow transplantation into Ldlr-KO mice, single-cell RNA-Seq of atherosclerotic plaque cells, flow cytometry, efferocytosis assay","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo genetic KO with BM transfer, scRNA-Seq, and functional efferocytosis assay; multiple orthogonal methods","pmids":["34003795"],"is_preprint":false},{"year":2022,"finding":"SETDB2 deposits H3K9me3 at the NRF2 promoter to suppress NRF2 transcription in lung adenocarcinoma cells; reduced SETDB2 activates NRF2 and its downstream targets (NQO1, FTH1, ME1), promotes malignant processes, and reduces ROS-induced apoptosis; SETDB2 overexpression suppresses tumor progression in vivo and sensitizes cells to chemotherapy.","method":"ChIP-qPCR (H3K9me3 at NRF2 promoter), shRNA/overexpression in LUAD cells, in vivo tumor assay, GSEA","journal":"Cancer medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR for direct promoter methylation plus in vivo functional experiments, single lab","pmids":["36504353"],"is_preprint":false},{"year":2023,"finding":"In aortic macrophages, IFNβ regulates SETDB2 expression via JAK/STAT signaling; SETDB2 deposits H3K9me3 at TIMP1-3 gene promoters to suppress TIMP1-3 transcription, leading to unregulated MMP activity; myeloid-specific Setdb2 KO mice are protected from AAA formation with increased TIMP expression and preserved aortic architecture; JAK/STAT inhibitor Tofacitinib limits SETDB2 expression in aortic macrophages.","method":"Myeloid-specific Setdb2 KO mice, scRNA-Seq, ChIP (H3K9me3 at TIMP1-3 promoters), angiotensin II/high-fat diet AAA model, pharmacologic JAK inhibition","journal":"Annals of surgery","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO model with ChIP, scRNA-Seq, pharmacologic validation, and human tissue analysis; multiple orthogonal methods","pmids":["37325923"],"is_preprint":false},{"year":2024,"finding":"SETDB2 interacts with BUBR1 and is required for CDC20 binding to BUBR1 and to the APC/C complex, and for CYCLIN B1 degradation to ensure accurate chromosome segregation and mitosis; these functions are independent of SETDB2's histone methyltransferase activity.","method":"Co-immunoprecipitation (SETDB2–BUBR1, CDC20–BUBR1/APC/C interactions), methyltransferase-dead mutant analysis, CYCLIN B1 degradation assay, mitosis assays","journal":"FEBS open bio","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and catalytic mutant analysis establishing non-enzymatic function, single lab","pmids":["38151757"],"is_preprint":false},{"year":2024,"finding":"STAT3 is required for SETDB2 expression in macrophages; paradoxically, STAT3 also acts as a binding partner of SETDB2 and represses SETDB2 activity by inhibiting its interaction with the NF-κB component RELA, leading to increased NF-κB-mediated inflammatory gene expression; SETDB2 suppresses inflammatory gene programs by inhibiting chromatin accessibility at NF-κB-dependent promoters; STAT3/SETDB2 binding is increased in diabetic wound macrophages.","method":"ATAC-Seq, RNA-Seq of myeloid-specific Setdb2 and STAT3 KO wound macrophages, Co-immunoprecipitation (STAT3–SETDB2, SETDB2–RELA interactions)","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — ATAC-Seq + RNA-Seq + Co-IP in genetic KO models with human diabetic tissue validation; multiple orthogonal methods","pmids":["39435663"],"is_preprint":false},{"year":2024,"finding":"The annotated methyl-CpG-binding domain (MBD) of SETDB2 does not bind DNA but instead functions as a protein-protein interaction domain that binds a cystine-rich domain of C11orf46, as determined by structural characterization.","method":"Structural characterization of MBD domain (referenced crystallographic/structural study by Mahana et al.)","journal":"Structure","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — structural finding (domain function redefined) but described only in a commentary citing the primary structural paper; single structural study","pmids":["38458157"],"is_preprint":false},{"year":2025,"finding":"TNF-α increases Setdb2 expression in fibroblasts via JAK1,3/STAT3 signaling; elevated SETDB2 represses fibroblast-to-myofibroblast transition; pharmacologic or genetic inhibition of JAK1,3/STAT3 reduces Setdb2 and improves myofibroblast gene expression; fibroblast-specific SETDB2 knockdown improves diabetic wound repair.","method":"Murine transgenic models, JAK inhibitor treatment, fibroblast-specific SETDB2 knockdown, TNF-α receptor blockade, macrophage supernatant stimulation","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo fibroblast-specific KD plus pharmacologic pathway manipulation and human tissue validation; multiple orthogonal methods in single lab","pmids":["41277557"],"is_preprint":false},{"year":2025,"finding":"SETDB2 regulates macrophage trained immunity through two distinct mechanisms: (1) positively regulating glycolytic and inflammatory pathway genes via enhancer-promoter chromatin looping independently of its H3K9 methyltransferase activity; (2) depositing H3K9me3 at promoters to repress interferon response pathway genes. Only mechanism (1) operates in response to sterile inflammatory stimuli, while both operate in response to pathogenic (β-glucan) training.","method":"Genetic mouse models, genomic analysis (ChIP, chromosome conformation), methyltransferase-dead mutant, β-glucan and Western diet/oxLDL trained immunity models","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genomic methods with genetic models; preprint, not yet peer-reviewed","pmids":["40166182"],"is_preprint":true},{"year":2025,"finding":"SETDB2 deposits H3K9me3 at the Smad3 promoter in podocytes, repressing SMAD3 expression and activation to preserve podocyte function in diabetic kidney disease; TCF21 is identified as a direct upstream transcriptional activator of Setdb2 by binding to its promoter; podocyte-specific SETDB2 deficiency accelerates DKD progression.","method":"Podocyte-specific Setdb2 KO mice, ChIP (H3K9me3 at Smad3 promoter), promoter binding assay for TCF21, human DKD patient glomerular samples","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo cell-type-specific KO, ChIP, upstream regulator promoter binding assay, human disease correlation; multiple orthogonal methods","pmids":["41316884"],"is_preprint":false},{"year":2025,"finding":"SETDB2 deposits H3K9me3 at two sites in the TFRC promoter, repressing TFRC expression; this suppresses the TFRC-STEAP3-DMT1 iron uptake axis, modulating cellular Fe2+ and ROS levels in esophageal squamous cell carcinoma; TFRC knockdown rescues proliferation changes caused by SETDB2 knockdown, placing TFRC as an essential mediator downstream of SETDB2.","method":"ChIP (H3K9me3 at TFRC promoter), shRNA knockdown, Fe2+/ROS measurement, rescue experiments, in vivo tumor models","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional rescue epistasis, single lab","pmids":["40645600"],"is_preprint":false},{"year":2026,"finding":"SETDB2 deposits H3K9me3 at the SRSF1 promoter, repressing SRSF1 (splicing factor) expression; reduced SRSF1 decreases the proportion of functional (tumor-suppressive) SHP-1 splice forms, leading to sustained JAK/STAT3 activation and enhanced tumor immunosuppression in hepatocellular carcinoma; this SETDB2/SRSF1/SHP-1/STAT3 axis drives immune escape.","method":"ChIP (H3K9me3 at SRSF1 promoter), SETDB2 KD functional experiments, PDX model comparison (responders vs. non-responders), RNA-seq + proteomics","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional KD and PDX model; multi-method single lab study","pmids":["41946995"],"is_preprint":false},{"year":2026,"finding":"SETDB2 upregulation in trigeminal ganglion neurons deposits H3K9me3 and blocks KLF4 transcription factor binding to the IDE (insulin-degrading enzyme) promoter, suppressing IDE expression and impairing CGRP degradation; this leads to increased CGRP levels and migraine-like pain behaviors; reversing SETDB2 upregulation reduces H3K9me3 and alleviates pain.","method":"Nitroglycerin-induced chronic migraine mouse model, ChIP (H3K9me3 at IDE promoter, KLF4 binding assay), SETDB2 overexpression/knockdown in TG neurons, human CSF SETDB2 measurement","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating KLF4 displacement plus in vivo functional model and human samples; single lab","pmids":["41880325"],"is_preprint":false},{"year":2026,"finding":"SETDB2 knockdown in macrophages reduces H3K9me3 and upregulates ALPK1 expression; ALPK1 overexpression reverses the M2-polarizing and chondroprotective effects of SETDB2 overexpression, establishing ALPK1 as a direct H3K9me3-regulated downstream target of SETDB2 that controls macrophage polarization in knee osteoarthritis.","method":"ChIP-qPCR (H3K9me3 at ALPK1 promoter), shRNA knockdown, SETDB2 overexpression, co-culture experiments, KOA mouse model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR plus functional epistasis rescue with ALPK1 overexpression; single lab","pmids":["41482828"],"is_preprint":false},{"year":2024,"finding":"Setdb2 KO in macrophages promotes M2 polarization through upregulation of PI3K/Akt signaling; PI3K inhibitor LY294002 nullifies the M2-polarizing effect of Setdb2 KO, placing Setdb2 as a repressor of PI3K/Akt-driven alternative macrophage activation.","method":"Conditional Setdb2 KO in mice, BMDM culture, RNA sequencing, Western blotting, PI3K inhibitor treatment","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus pharmacologic epistasis with RNA-seq; single lab","pmids":["38905784"],"is_preprint":false}],"current_model":"SETDB2 is a histone H3 lysine 9 (H3K9) trimethyltransferase that deposits the repressive H3K9me3 mark at promoters of NF-κB target genes, tumor suppressors, and other loci to silence transcription; its expression is induced by type I IFN/JAK-STAT signaling in immune cells, and it additionally functions independently of its methyltransferase activity by interacting with BUBR1 to facilitate CDC20–APC/C binding and CYCLIN B1 degradation for accurate chromosome segregation, and by forming a complex with STAT3 that modulates its own activity toward NF-κB/RELA, collectively placing SETDB2 as a central epigenetic and non-enzymatic regulator of macrophage inflammation, lipid metabolism, cell cycle, and developmental patterning."},"narrative":{"mechanistic_narrative":"SETDB2 (CLLD8/KMT1F) is a SET-domain histone H3 lysine 9 (H3K9) trimethyltransferase that establishes repressive H3K9me3 chromatin at defined promoters to silence transcription, acting most prominently as a brake on inflammatory and developmental gene programs [PMID:20404330, PMID:25419628, PMID:31350176]. At constitutive heterochromatin it methylates H3K9 at interspersed repeats and centromere-associated sequences, recruits HP1, and is required for centromere protein loading and timely mitosis, working together with SUV39H1 [PMID:20404330]. In innate immunity, SETDB2 is induced downstream of type I interferon (IFNβ) via JAK/STAT3 signaling and deposits H3K9me3 at NF-κB binding sites on cytokine and chemokine promoters (e.g. Cxcl1), restraining inflammation and enabling the inflammatory-to-reparative macrophage transition [PMID:25419628, PMID:31350176, PMID:34479991]; STAT3 both drives SETDB2 expression and, paradoxically, binds SETDB2 to limit its interaction with RELA, thereby tuning NF-κB output [PMID:39435663]. This IFNβ–SETDB2 axis governs macrophage and fibroblast behavior across diabetic wound healing, atherosclerosis, and aortic aneurysm, where SETDB2 silences targets including TIMP1-3 and modulates xanthine oxidase and macrophage polarization [PMID:31350176, PMID:34003795, PMID:37325923, PMID:38905784]. SETDB2 functions as a recurrent transcriptional repressor in cancer and disease by trimethylating promoters of tumor suppressors and stress regulators — WWOX, CADM1, CDKN2C, NRF2, TFRC, SRSF1, Smad3 and IDE — with cell-type-specific upstream activators such as E2A-PBX1 and TCF21 [PMID:27572307, PMID:29694893, PMID:36504353, PMID:41316884, PMID:40645600, PMID:41880325]. In zebrafish it patterns the embryonic axis by restricting the dorsal organizer and convergent-extension movements through suppression of fgf8 and dvr1 signaling [PMID:20133783, PMID:24892953]. Beyond catalysis, SETDB2 also acts non-enzymatically: it binds BUBR1 to promote CDC20–APC/C assembly and CYCLIN B1 degradation for accurate chromosome segregation, and it can positively regulate inflammatory/glycolytic genes via enhancer-promoter looping independent of its methyltransferase activity [PMID:38151757, PMID:40166182]. Consistent with a protein-interaction role, its annotated methyl-CpG-binding domain does not bind DNA but mediates binding to C11orf46 [PMID:38458157].","teleology":[{"year":2001,"claim":"Defining SETDB2's domain architecture first raised the hypothesis that it acts in methylation-dependent transcriptional repression.","evidence":"Sequence/domain analysis identifying MBD, preSET, and SET domains at 13q14","pmids":["11306461"],"confidence":"Low","gaps":["Computational prediction only, no enzymatic or functional assay","Catalytic substrate not demonstrated","MBD DNA-binding inferred but not tested"]},{"year":2010,"claim":"Established SETDB2 as a bona fide H3K9 trimethyltransferase at heterochromatin required for mitotic fidelity, moving it from predicted to functional enzyme.","evidence":"siRNA knockdown, ChIP for H3K9me3 at repeats/centromeres, HP1 and CENP localization, cell cycle timing","pmids":["20404330"],"confidence":"High","gaps":["Did not resolve direct versus indirect H3K9me3 deposition in vitro","Relationship between heterochromatin and gene-specific roles unclear","Mechanism of HP1 recruitment not dissected"]},{"year":2010,"claim":"Showed SETDB2 controls vertebrate body-axis patterning by acting upstream of Fgf8, the first developmental function in vivo.","evidence":"Morpholino knockdown in zebrafish with mRNA and dominant-negative FGFR rescue, in situ hybridization","pmids":["20133783"],"confidence":"High","gaps":["Whether fgf8 repression is via direct promoter H3K9me3 not shown","Catalytic dependence not tested in this system","Mammalian developmental relevance untested"]},{"year":2014,"claim":"Defined SETDB2 as an IFN-induced epigenetic brake on NF-κB target genes, linking type I IFN signaling to chromatin repression of inflammation.","evidence":"Hypomorphic gene-trap mice, ChIP for H3K9me3 at Cxcl1, neutrophil quantification, superinfection model; plus zebrafish dvr1 epistasis","pmids":["25419628","24892953"],"confidence":"High","gaps":["How IFN induces SETDB2 transcription not mapped","Recruitment to specific NF-κB promoters undefined","Direct enzymatic vs scaffolding contribution not separated"]},{"year":2016,"claim":"Extended SETDB2 to metabolic and oncogenic gene silencing, showing it represses lipid-synthesis regulators and tumor suppressors via promoter H3K9me3.","evidence":"ChIP, chromatin looping, knockdown in hepatocytes/ob/ob mice (Insig2a/SREBP); ChIP/knockdown in gastric cancer (WWOX, CADM1)","pmids":["27568546","27572307"],"confidence":"High","gaps":["Targeting specificity to individual promoters unexplained","Whether GR-SETDB2 cooperation is direct binding unknown","Generality of tumor-suppressor silencing across cancers untested"]},{"year":2018,"claim":"Placed SETDB2 within defined oncogenic transcriptional circuits as an effector silencing cell-cycle inhibitors.","evidence":"ChIP for H3K9me3 at CDKN2C, shRNA in vitro/xenograft, E2A-PBX1 promoter binding; monocyte KO/overexpression in superinfection","pmids":["29694893","29749709"],"confidence":"High","gaps":["E2A-PBX1 → SETDB2 induction mechanism not fully resolved","Direct recruitment to CDKN2C promoter not shown","Breadth of repressed loci undefined"]},{"year":2019,"claim":"Demonstrated through cell-type-specific deletion that the IFNβ–SETDB2 axis governs macrophage phenotype transitions and is dysregulated in diabetes.","evidence":"Myeloid-specific Setdb2 KO mice, ChIP for H3K9me3 at NF-κB sites, IFNβ treatment, human/murine wound macrophages","pmids":["31350176","30670717"],"confidence":"High","gaps":["Molecular basis of impaired IFNβ-SETDB2 axis in diabetes unclear","How SETDB2 selects NF-κB-bound promoters unknown","Xanthine oxidase regulation mechanism not detailed"]},{"year":2020,"claim":"Revealed a non-histone substrate and protein-stabilizing role, broadening SETDB2's catalytic repertoire beyond histones.","evidence":"Co-IP, in vitro methylation of ΔNp63α, shRNA, mammosphere and tumor-initiation rescue","pmids":["32549764"],"confidence":"Medium","gaps":["Methylation site on ΔNp63α not mapped","Mechanism of methylation-dependent stabilization unclear","Single-lab observation"]},{"year":2021,"claim":"Confirmed in vivo that loss of SETDB2 unleashes vascular and infection-driven inflammation, establishing protective anti-inflammatory function across disease contexts.","evidence":"Myeloid-specific KO mice, scRNA-Seq, ChIP, JAK/STAT manipulation, human SARS-CoV-2 and atherosclerosis samples","pmids":["34479991","34003795"],"confidence":"High","gaps":["Why coronavirus lowers IFNβ-JAK1/STAT3-SETDB2 signaling unresolved","Efferocytosis defect mechanism not pinned to specific targets","M1-restricted induction mechanism unknown"]},{"year":2023,"claim":"Mapped a specific repressed target program (TIMP1-3) linking SETDB2 loss to matrix remodeling disease, and validated pharmacologic JAK modulation of SETDB2.","evidence":"Myeloid-specific KO, scRNA-Seq, ChIP at TIMP1-3, AAA model, Tofacitinib; NRF2 ChIP/functional work in LUAD","pmids":["37325923","36504353"],"confidence":"High","gaps":["Promoter-selection determinants for TIMP genes unknown","Whether JAK inhibition acts solely through SETDB2 unclear","NRF2 axis is medium-confidence single lab"]},{"year":2024,"claim":"Defined a methyltransferase-independent mitotic role and a paradoxical STAT3 partnership, separating SETDB2's enzymatic and scaffolding functions.","evidence":"Reciprocal Co-IP (BUBR1, CDC20-APC/C; STAT3-SETDB2, SETDB2-RELA), catalytic-dead mutants, ATAC/RNA-Seq, CYCLIN B1 degradation assays","pmids":["38151757","39435663","38458157","38905784"],"confidence":"High","gaps":["Structural basis of SETDB2-BUBR1 and SETDB2-RELA contacts undefined","How STAT3 both induces and inhibits SETDB2 spatially/temporally unclear","MBD-C11orf46 interaction functional consequence not established"]},{"year":2025,"claim":"Expanded SETDB2 to a broad disease-relevant repressor acting on splicing, iron metabolism, fibrosis, kidney, and trained-immunity programs through both catalytic and looping mechanisms.","evidence":"Cell-type-specific KO/KD models with ChIP at Smad3, TFRC, SRSF1, IDE, ALPK1; TCF21/KLF4 promoter assays; chromosome conformation and catalytic-dead analysis","pmids":["41277557","41316884","40645600","41946995","41880325","41482828","40166182"],"confidence":"High","gaps":["Determinants directing SETDB2 to such diverse promoters unknown","Balance between repressive H3K9me3 and activating looping not generalized","Several axes from single-lab studies awaiting replication"]},{"year":null,"claim":"How SETDB2 achieves locus and substrate specificity — selecting particular NF-κB, tumor-suppressor, and metabolic promoters versus deploying its non-enzymatic looping/scaffolding activity — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model for promoter targeting","Switch between catalytic repression and enhancer-promoter looping undefined","Structural data on SETDB2 complexes limited"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,3,6,9,11]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[11]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[1,9]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,6,7]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[16,18]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,3,6]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[1,3,9]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,9,12,13,17]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[6,7,14,21]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[1,16]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,4]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[13,15,21]}],"complexes":["APC/C (functional association via BUBR1/CDC20)"],"partners":["BUBR1","CDC20","STAT3","RELA","C11ORF46","SUV39H1","TP63"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q96T68","full_name":"Histone-lysine N-methyltransferase SETDB2","aliases":["Chronic lymphocytic leukemia deletion region gene 8 protein","Lysine N-methyltransferase 1F","SET domain bifurcated 2"],"length_aa":719,"mass_kda":81.9,"function":"Histone methyltransferase involved in left-right axis specification in early development and mitosis. Specifically trimethylates 'Lys-9' of histone H3 (H3K9me3). H3K9me3 is a specific tag for epigenetic transcriptional repression that recruits HP1 (CBX1, CBX3 and/or CBX5) proteins to methylated histones. Contributes to H3K9me3 in both the interspersed repetitive elements and centromere-associated repeats. Plays a role in chromosome condensation and segregation during mitosis","subcellular_location":"Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/Q96T68/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SETDB2","classification":"Not Classified","n_dependent_lines":10,"n_total_lines":1208,"dependency_fraction":0.008278145695364239},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SETDB2","total_profiled":1310},"omim":[{"mim_id":"607865","title":"SET DOMAIN PROTEIN, BIFURCATED, 2; SETDB2","url":"https://www.omim.org/entry/607865"},{"mim_id":"607796","title":"PHD FINGER PROTEIN 11; PHF11","url":"https://www.omim.org/entry/607796"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SETDB2"},"hgnc":{"alias_symbol":["CLLD8","CLLL8","KMT1F"],"prev_symbol":["C13orf4"]},"alphafold":{"accession":"Q96T68","domains":[{"cath_id":"3.30.890","chopping":"150-213","consensus_level":"high","plddt":86.7753,"start":150,"end":213},{"cath_id":"2.170.270.10","chopping":"242-408_635-690","consensus_level":"high","plddt":88.665,"start":242,"end":690},{"cath_id":"1.10.287","chopping":"19-55","consensus_level":"medium","plddt":84.3408,"start":19,"end":55}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96T68","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96T68-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96T68-F1-predicted_aligned_error_v6.png","plddt_mean":62.34},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SETDB2","jax_strain_url":"https://www.jax.org/strain/search?query=SETDB2"},"sequence":{"accession":"Q96T68","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96T68.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96T68/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96T68"}},"corpus_meta":[{"pmid":"31350176","id":"PMC_31350176","title":"The Histone Methyltransferase Setdb2 Modulates Macrophage Phenotype and Uric Acid Production in Diabetic Wound Repair.","date":"2019","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/31350176","citation_count":124,"is_preprint":false},{"pmid":"25419628","id":"PMC_25419628","title":"The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection.","date":"2014","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25419628","citation_count":120,"is_preprint":false},{"pmid":"11306461","id":"PMC_11306461","title":"Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11306461","citation_count":84,"is_preprint":false},{"pmid":"30850015","id":"PMC_30850015","title":"Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming.","date":"2019","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/30850015","citation_count":71,"is_preprint":false},{"pmid":"20404330","id":"PMC_20404330","title":"CLLD8/KMT1F is a lysine methyltransferase that is important for chromosome segregation.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20404330","citation_count":67,"is_preprint":false},{"pmid":"27568546","id":"PMC_27568546","title":"SETDB2 Links Glucocorticoid to Lipid Metabolism through Insig2a Regulation.","date":"2016","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/27568546","citation_count":57,"is_preprint":false},{"pmid":"20133783","id":"PMC_20133783","title":"Setdb2 restricts dorsal organizer territory and regulates left-right asymmetry through suppressing fgf8 activity.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20133783","citation_count":44,"is_preprint":false},{"pmid":"34479991","id":"PMC_34479991","title":"Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34479991","citation_count":32,"is_preprint":false},{"pmid":"29694893","id":"PMC_29694893","title":"SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29694893","citation_count":29,"is_preprint":false},{"pmid":"34003795","id":"PMC_34003795","title":"Deficiency of histone lysine methyltransferase SETDB2 in hematopoietic cells promotes vascular inflammation and accelerates atherosclerosis.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/34003795","citation_count":29,"is_preprint":false},{"pmid":"27572307","id":"PMC_27572307","title":"Oncogenic roles of the SETDB2 histone methyltransferase in gastric cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27572307","citation_count":28,"is_preprint":false},{"pmid":"24892953","id":"PMC_24892953","title":"Setdb2 controls convergence and extension movements during zebrafish gastrulation by transcriptional regulation of dvr1.","date":"2014","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/24892953","citation_count":19,"is_preprint":false},{"pmid":"37325923","id":"PMC_37325923","title":"The Histone Methyltransferase SETDB2 Modulates Tissue Inhibitors of Metalloproteinase-Matrix Metalloproteinase Activity During Abdominal Aortic Aneurysm Development.","date":"2023","source":"Annals of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/37325923","citation_count":16,"is_preprint":false},{"pmid":"30670717","id":"PMC_30670717","title":"Abrogated Caveolin-1 expression via histone modification enzyme Setdb2 regulates brain edema in a mouse model of influenza-associated encephalopathy.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30670717","citation_count":15,"is_preprint":false},{"pmid":"39435663","id":"PMC_39435663","title":"The STAT3/SETDB2 axis dictates NF-κB-mediated inflammation in macrophages during wound repair.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/39435663","citation_count":14,"is_preprint":false},{"pmid":"26572639","id":"PMC_26572639","title":"Left-Right Axis Differentiation and Functional Lateralization: a Haplotype in the Methyltransferase Encoding Gene SETDB2 Might Mediate Handedness in Healthy Adults.","date":"2015","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/26572639","citation_count":14,"is_preprint":false},{"pmid":"32549764","id":"PMC_32549764","title":"SETDB2 promoted breast cancer stem cell maintenance by interaction with and stabilization of ΔNp63α protein.","date":"2020","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32549764","citation_count":11,"is_preprint":false},{"pmid":"37195726","id":"PMC_37195726","title":"THE CRITICAL ROLE OF THE HISTONE MODIFICATION ENZYME SETDB2 IN THE PATHOGENESIS OF ACUTE RESPIRATORY DISTRESS SYNDROME.","date":"2023","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/37195726","citation_count":7,"is_preprint":false},{"pmid":"26378653","id":"PMC_26378653","title":"A functional AT/G polymorphism in the 5'-untranslated region of SETDB2 in the IgE locus on human chromosome 13q14.","date":"2015","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/26378653","citation_count":7,"is_preprint":false},{"pmid":"29234167","id":"PMC_29234167","title":"The SETDB2 locus: evidence for a genetic link between handedness and atopic disease.","date":"2017","source":"Heredity","url":"https://pubmed.ncbi.nlm.nih.gov/29234167","citation_count":7,"is_preprint":false},{"pmid":"36504353","id":"PMC_36504353","title":"Histone lysine methyltransferase SETDB2 suppresses NRF2 to restrict tumor progression and modulates chemotherapy sensitivity in lung adenocarcinoma.","date":"2022","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36504353","citation_count":6,"is_preprint":false},{"pmid":"32099474","id":"PMC_32099474","title":"Oncogenic Roles Of A Histone Methyltransferase SETDB2 In AML1-ETO Positive AML.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/32099474","citation_count":4,"is_preprint":false},{"pmid":"38905784","id":"PMC_38905784","title":"Downregulation of Setdb2 promotes alternative activation of macrophages via the PI3K/Akt pathway to attenuate NAFLD after sleeve gastrectomy.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38905784","citation_count":4,"is_preprint":false},{"pmid":"29749709","id":"PMC_29749709","title":"Bacteria-induced susceptibility to Candida albicans super-infection in mice via monocyte methyltransferase Setdb2.","date":"2018","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/29749709","citation_count":4,"is_preprint":false},{"pmid":"40166182","id":"PMC_40166182","title":"Setdb2 Regulates Inflammatory Trigger-Induced Trained Immunity of Macrophages Through Two Different Epigenetic Mechanisms.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40166182","citation_count":2,"is_preprint":false},{"pmid":"40645600","id":"PMC_40645600","title":"SETDB2 participates in iron metabolism in esophageal squamous cell carcinoma via H3K9me3-mediated TFRC silencing.","date":"2025","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40645600","citation_count":1,"is_preprint":false},{"pmid":"41482828","id":"PMC_41482828","title":"SETDB2 Alleviates Knee Osteoarthritis Progression by Promoting M2-Like Macrophage Polarization via Targeting ALPK1.","date":"2026","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/41482828","citation_count":1,"is_preprint":false},{"pmid":"41316884","id":"PMC_41316884","title":"SETDB2 Mitigates Podocyte Dysfunction in Diabetic Kidney Disease Through Epigenetic Silencing of SMAD3.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41316884","citation_count":1,"is_preprint":false},{"pmid":"38151757","id":"PMC_38151757","title":"SETDB2 interacts with BUBR1 to induce accurate chromosome segregation independently of its histone methyltransferase activity.","date":"2024","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/38151757","citation_count":1,"is_preprint":false},{"pmid":"41277557","id":"PMC_41277557","title":"TNF-α represses fibroblast to myofibroblast transition through the histone methyltransferase Setdb2.","date":"2025","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/41277557","citation_count":1,"is_preprint":false},{"pmid":"40502770","id":"PMC_40502770","title":"Setdb2 Regulates Inflammatory Trigger-Induced Trained Immunity of Macrophages Through Two Different Epigenetic Mechanisms.","date":"2025","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/40502770","citation_count":1,"is_preprint":false},{"pmid":"38458157","id":"PMC_38458157","title":"One form and two functions: MBD of SETDB2 is a protein-interacting domain.","date":"2024","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/38458157","citation_count":1,"is_preprint":false},{"pmid":"41946995","id":"PMC_41946995","title":"SETDB2 induces abnormal SHP-1 splicing and promotes immunosuppression in hepatocellular carcinoma.","date":"2026","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/41946995","citation_count":0,"is_preprint":false},{"pmid":"41880325","id":"PMC_41880325","title":"SETDB2-mediated transcriptional repression of IDE in sensory neurons promotes migraine-like pain behaviors in mice.","date":"2026","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/41880325","citation_count":0,"is_preprint":false},{"pmid":"42157429","id":"PMC_42157429","title":"Casticin promotes M2 macrophage polarisation and dorsal root ganglion neuronal autophagy to alleviate cold hyperalgesia in knee osteoarthritis by regulating histone-lysine N-methyltransferase (SETDB2).","date":"2026","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/42157429","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":19318,"output_tokens":7066,"usd":0.081972,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16242,"output_tokens":4921,"usd":0.102117,"stage2_stop_reason":"end_turn"},"total_usd":0.184089,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"SETDB2 (CLLD8) contains a methyl-CpG binding domain, a preSET domain, and a SET domain, suggesting it functions in methylation-mediated transcriptional repression; identified as a novel gene at chromosome 13q14.\",\n      \"method\": \"Sequence analysis and domain characterization\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational domain prediction only, no functional experiments performed in this paper\",\n      \"pmids\": [\"11306461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SETDB2/CLLD8/KMT1F catalyzes trimethylation of histone H3K9 at interspersed repetitive elements and centromere-associated repeats, recruits heterochromatin protein 1 (HP1) to centromeres, and its depletion causes loss of CENP proteins and delayed mitosis, establishing a role in chromosome condensation and segregation. It acts in concert with SUV39H1/KMT1A.\",\n      \"method\": \"siRNA knockdown, ChIP, immunofluorescence, cell cycle analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (ChIP for H3K9me3, HP1 recruitment assay, CENP localization, mitosis timing) in a single focused study\",\n      \"pmids\": [\"20404330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In zebrafish, Setdb2 (H3K9 methyltransferase) restricts dorsal organizer territory and regulates left-right asymmetry by suppressing fgf8 expression; knockdown expands organizer markers and increases fgf8 mRNA, and these defects are rescued by dominant-negative FGF receptor or fgf8 knockdown, placing Setdb2 upstream of Fgf8 signaling.\",\n      \"method\": \"Morpholino knockdown in zebrafish embryos, mRNA rescue, dominant-negative receptor epistasis, in situ hybridization\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with rescue experiments and multiple markers across two independent suppression strategies\",\n      \"pmids\": [\"20133783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In influenza-infected mice, Setdb2 expression is induced by type I interferon signaling; Setdb2 occupies the Cxcl1 promoter and is required for H3K9me3 deposition there, repressing CXCL1 and other NF-κB target genes; hypomorphic Setdb2 mice show increased neutrophil infiltration and reduced susceptibility to bacterial superinfection, placing Setdb2 as a crosstalk mediator between type I IFN and NF-κB pathways.\",\n      \"method\": \"Gene-trap hypomorphic mouse model, ChIP (H3K9me3 at Cxcl1 promoter), gene expression analysis, neutrophil infiltration quantification\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model with ChIP demonstrating direct promoter occupancy and H3K9me3 deposition, replicated across multiple NF-κB target genes\",\n      \"pmids\": [\"25419628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In zebrafish, Setdb2 regulates convergence and extension (C&E) movements during gastrulation by transcriptionally suppressing dvr1 (a TGF-β ligand) to an appropriate level; both knockdown and overexpression of dvr1 phenocopy C&E defects, placing Setdb2-dvr1 as a critical transcriptional cascade for body axis formation.\",\n      \"method\": \"Morpholino knockdown, epistasis rescue experiments, in situ hybridization in zebrafish embryos\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with rescue in a vertebrate developmental model, single lab\",\n      \"pmids\": [\"24892953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SETDB2 is induced by glucocorticoid receptor (GR) signaling in liver; it facilitates GR chromatin enrichment and glucocorticoid-dependent enhancer-promoter interactions at the Insig2a locus, thereby inducing Insig2a expression during fasting; Insig2a in turn represses SREBP and limits lipid synthesis. SETDB2 knockdown prevents glucocorticoid-mediated inhibition of SREBP processing.\",\n      \"method\": \"ChIP, chromatin conformation (enhancer-promoter looping), siRNA knockdown in hepatocytes and in vivo, glucocorticoid treatment of ob/ob mice\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct chromatin enrichment plus functional knockdown with SREBP processing readout; multiple orthogonal methods in single lab\",\n      \"pmids\": [\"27568546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SETDB2 catalyzes H3K9me3 at the promoter regions of tumor suppressor genes WWOX and CADM1 in gastric cancer cells, repressing their transcription; ectopic SETDB2 protein is recruited to these promoters as shown by ChIP, and SETDB2 knockdown reduces global H3K9me3 and de-represses these genes.\",\n      \"method\": \"ChIP (H3K9me3), siRNA knockdown, microarray gene expression, SETDB2 overexpression\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional knockdown/overexpression with gene expression readout, single lab\",\n      \"pmids\": [\"27572307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SETDB2 is a direct transcriptional target of the E2A-PBX1 chimeric transcription factor in pre-BCR+ ALL; SETDB2 in turn deposits H3K9me3 at the CDKN2C promoter to repress this cell-cycle inhibitor, creating an oncogenic pathway downstream of E2A-PBX1 that silences a tumor suppressor.\",\n      \"method\": \"ChIP (H3K9me3 at CDKN2C promoter), shRNA knockdown in vitro and in vivo (xenograft), promoter analysis for E2A-PBX1 binding\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter ChIP, in vitro and in vivo knockdown, epistasis established with multiple orthogonal methods\",\n      \"pmids\": [\"29694893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In monocytes during systemic bacterial infection, elevated Setdb2 represses antifungal immunity genes (including Il1b, Tnf, Il6, Ifnb, Cxcl1) via H3K9 methylation at their promoters, promoting susceptibility to secondary Candida albicans super-infection; lentiviral Setdb2 knockout reverses this repression.\",\n      \"method\": \"Lentivirus-mediated Setdb2 knockout and overexpression in monocytes, gene expression analysis, murine super-infection model\",\n      \"journal\": \"Cellular microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic manipulation with functional readout, mechanism attributed to H3K9 methylation at promoters, single lab\",\n      \"pmids\": [\"29749709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In wound macrophages, SETDB2 trimethylates histone H3 (H3K9me3) at NF-κB binding sites on inflammatory cytokine gene promoters to suppress their transcription; SETDB2 expression is regulated by IFNβ, and myeloid-specific deletion of Setdb2 impairs transition from inflammatory to reparative macrophage phenotype; under diabetic conditions the IFNβ-Setdb2 axis is impaired. Additionally, SETDB2 regulates xanthine oxidase expression and thus uric acid production.\",\n      \"method\": \"Myeloid-specific Setdb2 knockout mice, ChIP (H3K9me3 at NF-κB sites), IFNβ treatment, wound macrophage isolation from diabetic patients and controls\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo myeloid-specific KO plus ChIP on human and murine samples, multiple orthogonal methods, published in high-impact journal\",\n      \"pmids\": [\"31350176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In influenza-associated encephalopathy, Setdb2 is upregulated in brain tissue and deposits H3K9me3 at the Caveolin-1 promoter to repress Caveolin-1 expression, contributing to blood-brain barrier breakdown; ChIP confirmed H3K9 methylation at the Caveolin-1 promoter.\",\n      \"method\": \"Murine IAE model (LPS + influenza), ChIP (H3K9me3 at Caveolin-1 promoter), gene expression profiling of 84 histone modification enzymes\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct promoter methylation plus in vivo model, single lab\",\n      \"pmids\": [\"30670717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SETDB2 interacts with and methylates ΔNp63α protein, stabilizing it; SETDB2 also upregulates transcription of ΔNp63α downstream Hedgehog pathway genes; SETDB2 knockdown reduces breast cancer stem cell population and mammosphere formation, and restoring ΔNp63α rescues the defect.\",\n      \"method\": \"Co-immunoprecipitation (SETDB2–ΔNp63α interaction), in vitro methylation assay, shRNA knockdown, mammosphere formation assay, in vivo tumor initiation\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and methylation assay for protein-protein interaction and PTM, functional rescue experiment, single lab\",\n      \"pmids\": [\"32549764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Coronavirus infection decreases SETDB2 in macrophages via reduction of IFNβ-JAK1/STAT3 signaling; decreased SETDB2 reduces H3K9me3 at NF-κB binding sites on inflammatory gene promoters, increasing macrophage-mediated inflammation; IFNβ treatment restores SETDB2 and represses inflammation; myeloid-specific Setdb2 KO mice show enhanced pathologic inflammation after coronavirus infection.\",\n      \"method\": \"Myeloid-specific Setdb2 KO mice, JAK/STAT pathway blockade, ChIP (H3K9me3 at NF-κB sites), IFNβ treatment, human SARS-CoV-2 patient monocytes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO model, ChIP, human patient samples, and pharmacologic pathway manipulation as orthogonal methods\",\n      \"pmids\": [\"34479991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SETDB2 deficiency in hematopoietic cells promotes vascular inflammation and accelerates atherosclerosis; loss of SETDB2 in macrophages leads to increased monocyte populations, enhanced inflammatory gene expression, macrophage accumulation in plaques, and attenuated efferocytosis; SETDB2 expression is upregulated in M1 but not M2 macrophages.\",\n      \"method\": \"Bone marrow transplantation into Ldlr-KO mice, single-cell RNA-Seq of atherosclerotic plaque cells, flow cytometry, efferocytosis assay\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic KO with BM transfer, scRNA-Seq, and functional efferocytosis assay; multiple orthogonal methods\",\n      \"pmids\": [\"34003795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SETDB2 deposits H3K9me3 at the NRF2 promoter to suppress NRF2 transcription in lung adenocarcinoma cells; reduced SETDB2 activates NRF2 and its downstream targets (NQO1, FTH1, ME1), promotes malignant processes, and reduces ROS-induced apoptosis; SETDB2 overexpression suppresses tumor progression in vivo and sensitizes cells to chemotherapy.\",\n      \"method\": \"ChIP-qPCR (H3K9me3 at NRF2 promoter), shRNA/overexpression in LUAD cells, in vivo tumor assay, GSEA\",\n      \"journal\": \"Cancer medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR for direct promoter methylation plus in vivo functional experiments, single lab\",\n      \"pmids\": [\"36504353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In aortic macrophages, IFNβ regulates SETDB2 expression via JAK/STAT signaling; SETDB2 deposits H3K9me3 at TIMP1-3 gene promoters to suppress TIMP1-3 transcription, leading to unregulated MMP activity; myeloid-specific Setdb2 KO mice are protected from AAA formation with increased TIMP expression and preserved aortic architecture; JAK/STAT inhibitor Tofacitinib limits SETDB2 expression in aortic macrophages.\",\n      \"method\": \"Myeloid-specific Setdb2 KO mice, scRNA-Seq, ChIP (H3K9me3 at TIMP1-3 promoters), angiotensin II/high-fat diet AAA model, pharmacologic JAK inhibition\",\n      \"journal\": \"Annals of surgery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO model with ChIP, scRNA-Seq, pharmacologic validation, and human tissue analysis; multiple orthogonal methods\",\n      \"pmids\": [\"37325923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SETDB2 interacts with BUBR1 and is required for CDC20 binding to BUBR1 and to the APC/C complex, and for CYCLIN B1 degradation to ensure accurate chromosome segregation and mitosis; these functions are independent of SETDB2's histone methyltransferase activity.\",\n      \"method\": \"Co-immunoprecipitation (SETDB2–BUBR1, CDC20–BUBR1/APC/C interactions), methyltransferase-dead mutant analysis, CYCLIN B1 degradation assay, mitosis assays\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and catalytic mutant analysis establishing non-enzymatic function, single lab\",\n      \"pmids\": [\"38151757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"STAT3 is required for SETDB2 expression in macrophages; paradoxically, STAT3 also acts as a binding partner of SETDB2 and represses SETDB2 activity by inhibiting its interaction with the NF-κB component RELA, leading to increased NF-κB-mediated inflammatory gene expression; SETDB2 suppresses inflammatory gene programs by inhibiting chromatin accessibility at NF-κB-dependent promoters; STAT3/SETDB2 binding is increased in diabetic wound macrophages.\",\n      \"method\": \"ATAC-Seq, RNA-Seq of myeloid-specific Setdb2 and STAT3 KO wound macrophages, Co-immunoprecipitation (STAT3–SETDB2, SETDB2–RELA interactions)\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ATAC-Seq + RNA-Seq + Co-IP in genetic KO models with human diabetic tissue validation; multiple orthogonal methods\",\n      \"pmids\": [\"39435663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The annotated methyl-CpG-binding domain (MBD) of SETDB2 does not bind DNA but instead functions as a protein-protein interaction domain that binds a cystine-rich domain of C11orf46, as determined by structural characterization.\",\n      \"method\": \"Structural characterization of MBD domain (referenced crystallographic/structural study by Mahana et al.)\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — structural finding (domain function redefined) but described only in a commentary citing the primary structural paper; single structural study\",\n      \"pmids\": [\"38458157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TNF-α increases Setdb2 expression in fibroblasts via JAK1,3/STAT3 signaling; elevated SETDB2 represses fibroblast-to-myofibroblast transition; pharmacologic or genetic inhibition of JAK1,3/STAT3 reduces Setdb2 and improves myofibroblast gene expression; fibroblast-specific SETDB2 knockdown improves diabetic wound repair.\",\n      \"method\": \"Murine transgenic models, JAK inhibitor treatment, fibroblast-specific SETDB2 knockdown, TNF-α receptor blockade, macrophage supernatant stimulation\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo fibroblast-specific KD plus pharmacologic pathway manipulation and human tissue validation; multiple orthogonal methods in single lab\",\n      \"pmids\": [\"41277557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SETDB2 regulates macrophage trained immunity through two distinct mechanisms: (1) positively regulating glycolytic and inflammatory pathway genes via enhancer-promoter chromatin looping independently of its H3K9 methyltransferase activity; (2) depositing H3K9me3 at promoters to repress interferon response pathway genes. Only mechanism (1) operates in response to sterile inflammatory stimuli, while both operate in response to pathogenic (β-glucan) training.\",\n      \"method\": \"Genetic mouse models, genomic analysis (ChIP, chromosome conformation), methyltransferase-dead mutant, β-glucan and Western diet/oxLDL trained immunity models\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genomic methods with genetic models; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"40166182\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SETDB2 deposits H3K9me3 at the Smad3 promoter in podocytes, repressing SMAD3 expression and activation to preserve podocyte function in diabetic kidney disease; TCF21 is identified as a direct upstream transcriptional activator of Setdb2 by binding to its promoter; podocyte-specific SETDB2 deficiency accelerates DKD progression.\",\n      \"method\": \"Podocyte-specific Setdb2 KO mice, ChIP (H3K9me3 at Smad3 promoter), promoter binding assay for TCF21, human DKD patient glomerular samples\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo cell-type-specific KO, ChIP, upstream regulator promoter binding assay, human disease correlation; multiple orthogonal methods\",\n      \"pmids\": [\"41316884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SETDB2 deposits H3K9me3 at two sites in the TFRC promoter, repressing TFRC expression; this suppresses the TFRC-STEAP3-DMT1 iron uptake axis, modulating cellular Fe2+ and ROS levels in esophageal squamous cell carcinoma; TFRC knockdown rescues proliferation changes caused by SETDB2 knockdown, placing TFRC as an essential mediator downstream of SETDB2.\",\n      \"method\": \"ChIP (H3K9me3 at TFRC promoter), shRNA knockdown, Fe2+/ROS measurement, rescue experiments, in vivo tumor models\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional rescue epistasis, single lab\",\n      \"pmids\": [\"40645600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"SETDB2 deposits H3K9me3 at the SRSF1 promoter, repressing SRSF1 (splicing factor) expression; reduced SRSF1 decreases the proportion of functional (tumor-suppressive) SHP-1 splice forms, leading to sustained JAK/STAT3 activation and enhanced tumor immunosuppression in hepatocellular carcinoma; this SETDB2/SRSF1/SHP-1/STAT3 axis drives immune escape.\",\n      \"method\": \"ChIP (H3K9me3 at SRSF1 promoter), SETDB2 KD functional experiments, PDX model comparison (responders vs. non-responders), RNA-seq + proteomics\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional KD and PDX model; multi-method single lab study\",\n      \"pmids\": [\"41946995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"SETDB2 upregulation in trigeminal ganglion neurons deposits H3K9me3 and blocks KLF4 transcription factor binding to the IDE (insulin-degrading enzyme) promoter, suppressing IDE expression and impairing CGRP degradation; this leads to increased CGRP levels and migraine-like pain behaviors; reversing SETDB2 upregulation reduces H3K9me3 and alleviates pain.\",\n      \"method\": \"Nitroglycerin-induced chronic migraine mouse model, ChIP (H3K9me3 at IDE promoter, KLF4 binding assay), SETDB2 overexpression/knockdown in TG neurons, human CSF SETDB2 measurement\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating KLF4 displacement plus in vivo functional model and human samples; single lab\",\n      \"pmids\": [\"41880325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"SETDB2 knockdown in macrophages reduces H3K9me3 and upregulates ALPK1 expression; ALPK1 overexpression reverses the M2-polarizing and chondroprotective effects of SETDB2 overexpression, establishing ALPK1 as a direct H3K9me3-regulated downstream target of SETDB2 that controls macrophage polarization in knee osteoarthritis.\",\n      \"method\": \"ChIP-qPCR (H3K9me3 at ALPK1 promoter), shRNA knockdown, SETDB2 overexpression, co-culture experiments, KOA mouse model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR plus functional epistasis rescue with ALPK1 overexpression; single lab\",\n      \"pmids\": [\"41482828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Setdb2 KO in macrophages promotes M2 polarization through upregulation of PI3K/Akt signaling; PI3K inhibitor LY294002 nullifies the M2-polarizing effect of Setdb2 KO, placing Setdb2 as a repressor of PI3K/Akt-driven alternative macrophage activation.\",\n      \"method\": \"Conditional Setdb2 KO in mice, BMDM culture, RNA sequencing, Western blotting, PI3K inhibitor treatment\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus pharmacologic epistasis with RNA-seq; single lab\",\n      \"pmids\": [\"38905784\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SETDB2 is a histone H3 lysine 9 (H3K9) trimethyltransferase that deposits the repressive H3K9me3 mark at promoters of NF-κB target genes, tumor suppressors, and other loci to silence transcription; its expression is induced by type I IFN/JAK-STAT signaling in immune cells, and it additionally functions independently of its methyltransferase activity by interacting with BUBR1 to facilitate CDC20–APC/C binding and CYCLIN B1 degradation for accurate chromosome segregation, and by forming a complex with STAT3 that modulates its own activity toward NF-κB/RELA, collectively placing SETDB2 as a central epigenetic and non-enzymatic regulator of macrophage inflammation, lipid metabolism, cell cycle, and developmental patterning.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SETDB2 (CLLD8/KMT1F) is a SET-domain histone H3 lysine 9 (H3K9) trimethyltransferase that establishes repressive H3K9me3 chromatin at defined promoters to silence transcription, acting most prominently as a brake on inflammatory and developmental gene programs [#1, #3, #9]. At constitutive heterochromatin it methylates H3K9 at interspersed repeats and centromere-associated sequences, recruits HP1, and is required for centromere protein loading and timely mitosis, working together with SUV39H1 [#1]. In innate immunity, SETDB2 is induced downstream of type I interferon (IFN\\u03b2) via JAK/STAT3 signaling and deposits H3K9me3 at NF-\\u03baB binding sites on cytokine and chemokine promoters (e.g. Cxcl1), restraining inflammation and enabling the inflammatory-to-reparative macrophage transition [#3, #9, #12]; STAT3 both drives SETDB2 expression and, paradoxically, binds SETDB2 to limit its interaction with RELA, thereby tuning NF-\\u03baB output [#17]. This IFN\\u03b2\\u2013SETDB2 axis governs macrophage and fibroblast behavior across diabetic wound healing, atherosclerosis, and aortic aneurysm, where SETDB2 silences targets including TIMP1-3 and modulates xanthine oxidase and macrophage polarization [#9, #13, #15, #26]. SETDB2 functions as a recurrent transcriptional repressor in cancer and disease by trimethylating promoters of tumor suppressors and stress regulators \\u2014 WWOX, CADM1, CDKN2C, NRF2, TFRC, SRSF1, Smad3 and IDE \\u2014 with cell-type-specific upstream activators such as E2A-PBX1 and TCF21 [#6, #7, #14, #21, #22, #24]. In zebrafish it patterns the embryonic axis by restricting the dorsal organizer and convergent-extension movements through suppression of fgf8 and dvr1 signaling [#2, #4]. Beyond catalysis, SETDB2 also acts non-enzymatically: it binds BUBR1 to promote CDC20\\u2013APC/C assembly and CYCLIN B1 degradation for accurate chromosome segregation, and it can positively regulate inflammatory/glycolytic genes via enhancer-promoter looping independent of its methyltransferase activity [#16, #20]. Consistent with a protein-interaction role, its annotated methyl-CpG-binding domain does not bind DNA but mediates binding to C11orf46 [#18].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Defining SETDB2's domain architecture first raised the hypothesis that it acts in methylation-dependent transcriptional repression.\",\n      \"evidence\": \"Sequence/domain analysis identifying MBD, preSET, and SET domains at 13q14\",\n      \"pmids\": [\"11306461\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Computational prediction only, no enzymatic or functional assay\", \"Catalytic substrate not demonstrated\", \"MBD DNA-binding inferred but not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established SETDB2 as a bona fide H3K9 trimethyltransferase at heterochromatin required for mitotic fidelity, moving it from predicted to functional enzyme.\",\n      \"evidence\": \"siRNA knockdown, ChIP for H3K9me3 at repeats/centromeres, HP1 and CENP localization, cell cycle timing\",\n      \"pmids\": [\"20404330\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve direct versus indirect H3K9me3 deposition in vitro\", \"Relationship between heterochromatin and gene-specific roles unclear\", \"Mechanism of HP1 recruitment not dissected\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed SETDB2 controls vertebrate body-axis patterning by acting upstream of Fgf8, the first developmental function in vivo.\",\n      \"evidence\": \"Morpholino knockdown in zebrafish with mRNA and dominant-negative FGFR rescue, in situ hybridization\",\n      \"pmids\": [\"20133783\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether fgf8 repression is via direct promoter H3K9me3 not shown\", \"Catalytic dependence not tested in this system\", \"Mammalian developmental relevance untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined SETDB2 as an IFN-induced epigenetic brake on NF-\\u03baB target genes, linking type I IFN signaling to chromatin repression of inflammation.\",\n      \"evidence\": \"Hypomorphic gene-trap mice, ChIP for H3K9me3 at Cxcl1, neutrophil quantification, superinfection model; plus zebrafish dvr1 epistasis\",\n      \"pmids\": [\"25419628\", \"24892953\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How IFN induces SETDB2 transcription not mapped\", \"Recruitment to specific NF-\\u03baB promoters undefined\", \"Direct enzymatic vs scaffolding contribution not separated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended SETDB2 to metabolic and oncogenic gene silencing, showing it represses lipid-synthesis regulators and tumor suppressors via promoter H3K9me3.\",\n      \"evidence\": \"ChIP, chromatin looping, knockdown in hepatocytes/ob/ob mice (Insig2a/SREBP); ChIP/knockdown in gastric cancer (WWOX, CADM1)\",\n      \"pmids\": [\"27568546\", \"27572307\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Targeting specificity to individual promoters unexplained\", \"Whether GR-SETDB2 cooperation is direct binding unknown\", \"Generality of tumor-suppressor silencing across cancers untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed SETDB2 within defined oncogenic transcriptional circuits as an effector silencing cell-cycle inhibitors.\",\n      \"evidence\": \"ChIP for H3K9me3 at CDKN2C, shRNA in vitro/xenograft, E2A-PBX1 promoter binding; monocyte KO/overexpression in superinfection\",\n      \"pmids\": [\"29694893\", \"29749709\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E2A-PBX1 \\u2192 SETDB2 induction mechanism not fully resolved\", \"Direct recruitment to CDKN2C promoter not shown\", \"Breadth of repressed loci undefined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated through cell-type-specific deletion that the IFN\\u03b2\\u2013SETDB2 axis governs macrophage phenotype transitions and is dysregulated in diabetes.\",\n      \"evidence\": \"Myeloid-specific Setdb2 KO mice, ChIP for H3K9me3 at NF-\\u03baB sites, IFN\\u03b2 treatment, human/murine wound macrophages\",\n      \"pmids\": [\"31350176\", \"30670717\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of impaired IFN\\u03b2-SETDB2 axis in diabetes unclear\", \"How SETDB2 selects NF-\\u03baB-bound promoters unknown\", \"Xanthine oxidase regulation mechanism not detailed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed a non-histone substrate and protein-stabilizing role, broadening SETDB2's catalytic repertoire beyond histones.\",\n      \"evidence\": \"Co-IP, in vitro methylation of \\u0394Np63\\u03b1, shRNA, mammosphere and tumor-initiation rescue\",\n      \"pmids\": [\"32549764\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Methylation site on \\u0394Np63\\u03b1 not mapped\", \"Mechanism of methylation-dependent stabilization unclear\", \"Single-lab observation\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Confirmed in vivo that loss of SETDB2 unleashes vascular and infection-driven inflammation, establishing protective anti-inflammatory function across disease contexts.\",\n      \"evidence\": \"Myeloid-specific KO mice, scRNA-Seq, ChIP, JAK/STAT manipulation, human SARS-CoV-2 and atherosclerosis samples\",\n      \"pmids\": [\"34479991\", \"34003795\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why coronavirus lowers IFN\\u03b2-JAK1/STAT3-SETDB2 signaling unresolved\", \"Efferocytosis defect mechanism not pinned to specific targets\", \"M1-restricted induction mechanism unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Mapped a specific repressed target program (TIMP1-3) linking SETDB2 loss to matrix remodeling disease, and validated pharmacologic JAK modulation of SETDB2.\",\n      \"evidence\": \"Myeloid-specific KO, scRNA-Seq, ChIP at TIMP1-3, AAA model, Tofacitinib; NRF2 ChIP/functional work in LUAD\",\n      \"pmids\": [\"37325923\", \"36504353\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter-selection determinants for TIMP genes unknown\", \"Whether JAK inhibition acts solely through SETDB2 unclear\", \"NRF2 axis is medium-confidence single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined a methyltransferase-independent mitotic role and a paradoxical STAT3 partnership, separating SETDB2's enzymatic and scaffolding functions.\",\n      \"evidence\": \"Reciprocal Co-IP (BUBR1, CDC20-APC/C; STAT3-SETDB2, SETDB2-RELA), catalytic-dead mutants, ATAC/RNA-Seq, CYCLIN B1 degradation assays\",\n      \"pmids\": [\"38151757\", \"39435663\", \"38458157\", \"38905784\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of SETDB2-BUBR1 and SETDB2-RELA contacts undefined\", \"How STAT3 both induces and inhibits SETDB2 spatially/temporally unclear\", \"MBD-C11orf46 interaction functional consequence not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Expanded SETDB2 to a broad disease-relevant repressor acting on splicing, iron metabolism, fibrosis, kidney, and trained-immunity programs through both catalytic and looping mechanisms.\",\n      \"evidence\": \"Cell-type-specific KO/KD models with ChIP at Smad3, TFRC, SRSF1, IDE, ALPK1; TCF21/KLF4 promoter assays; chromosome conformation and catalytic-dead analysis\",\n      \"pmids\": [\"41277557\", \"41316884\", \"40645600\", \"41946995\", \"41880325\", \"41482828\", \"40166182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants directing SETDB2 to such diverse promoters unknown\", \"Balance between repressive H3K9me3 and activating looping not generalized\", \"Several axes from single-lab studies awaiting replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SETDB2 achieves locus and substrate specificity \\u2014 selecting particular NF-\\u03baB, tumor-suppressor, and metabolic promoters versus deploying its non-enzymatic looping/scaffolding activity \\u2014 remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model for promoter targeting\", \"Switch between catalytic repression and enhancer-promoter looping undefined\", \"Structural data on SETDB2 complexes limited\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 3, 6, 9, 11]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [1, 9]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 6, 7]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [16, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 3, 6]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [1, 3, 9]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 9, 12, 13, 17]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [6, 7, 14, 21]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [1, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 4]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [13, 15, 21]}\n    ],\n    \"complexes\": [\"APC/C (functional association via BUBR1/CDC20)\"],\n    \"partners\": [\"BUBR1\", \"CDC20\", \"STAT3\", \"RELA\", \"C11orf46\", \"SUV39H1\", \"TP63\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}